Latest Fairmount Funds Management LLC Stock Portfolio
Fairmount Funds Management LLC Performance:
2024 Q3: 13.29%YTD: 21.22%2023: 15.06%
Performance for 2024 Q3 is 13.29%, and YTD is 21.22%, and 2023 is 15.06%.
About Fairmount Funds Management LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Fairmount Funds Management LLC reported an equity portfolio of $1.2 Billions as of 30 Sep, 2024.
The top stock holdings of Fairmount Funds Management LLC are AXSM, NUVL, . The fund has invested 17.2% of it's portfolio in AXSOME THERAPEUTICS INC and 14% of portfolio in NUVALENT INC.
The fund managers got completely rid off PROTAGONIST THERAPEUTICS INC (PTGX) and TERNS PHARMACEUTICALS INC (TERN) stocks. They significantly reduced their stock positions in BICYCLE THERAPEUTICS PLC (BCYC), NUVALENT INC (NUVL) and DIANTHUS THERAPEUTICS INC. Fairmount Funds Management LLC opened new stock positions in ORUKA THERAPEUTICS INC and DAY ONE BIOPHARMACEUTICALS INC (DAWN). The fund showed a lot of confidence in some stocks as they added substantially to VIRIDIAN THERAPEUTICS INC (VRDN).
The top stock holdings of Fairmount Funds Management LLC are AXSM, NUVL, . The fund has invested 17.2% of it's portfolio in AXSOME THERAPEUTICS INC and 14% of portfolio in NUVALENT INC.
The fund managers got completely rid off PROTAGONIST THERAPEUTICS INC (PTGX) and TERNS PHARMACEUTICALS INC (TERN) stocks. They significantly reduced their stock positions in BICYCLE THERAPEUTICS PLC (BCYC), NUVALENT INC (NUVL) and DIANTHUS THERAPEUTICS INC. Fairmount Funds Management LLC opened new stock positions in ORUKA THERAPEUTICS INC and DAY ONE BIOPHARMACEUTICALS INC (DAWN). The fund showed a lot of confidence in some stocks as they added substantially to VIRIDIAN THERAPEUTICS INC (VRDN).
Fairmount Funds Management LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Fairmount Funds Management LLC made a return of 13.29% in the last quarter. In trailing 12 months, it's portfolio return was 36.47%.
New Buys
| Ticker | $ Bought |
|---|---|
| oruka therapeutics inc | 78,724,200 |
| day one biopharmaceuticals inc | 43,231,000 |
| bicara therapeutics inc | 32,707,800 |
| zenas biopharma inc | 32,026,300 |
New stocks bought by Fairmount Funds Management LLC
Additions
| Ticker | % Inc. |
|---|---|
| viridian therapeutics inc | 86.68 |
Additions to existing portfolio by Fairmount Funds Management LLC
Reductions
| Ticker | % Reduced |
|---|---|
| bicycle therapeutics plc | -88.45 |
| nuvalent inc | -12.34 |
| dianthus therapeutics inc | -2.25 |
Fairmount Funds Management LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| protagonist therapeutics inc | -32,290,000 |
| terns pharmaceuticals inc | -5,100,660 |
Fairmount Funds Management LLC got rid off the above stocks
Sector Distribution
Fairmount Funds Management LLC has about 59.5% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 59.5 |
| Others | 40.5 |
Market Cap. Distribution
Fairmount Funds Management LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 40.5 |
| MID-CAP | 31.2 |
| SMALL-CAP | 28.3 |
Stocks belong to which Index?
About 49.7% of the stocks held by Fairmount Funds Management LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 50.3 |
| RUSSELL 2000 | 49.7 |
Fairmount Funds Management LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Fairmount Funds Management LLC
Fairmount Funds Management LLC has 15 stocks in it's portfolio. About 87.8% of the portfolio is in top 10 stocks. DAWN proved to be the most loss making stock for the portfolio. NUVL was the most profitable stock for Fairmount Funds Management LLC last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AGLE | spyre therapeutics inc | 9.58 | 4,018,100 | 118,172,000 | unchanged | 0.00 | ||
| ATXS | astria therapeutics inc | 3.17 | 3,554,130 | 39,131,000 | unchanged | 0.00 | ||
| AXSM | axsome therapeutics inc | 17.20 | 2,360,080 | 212,100,000 | unchanged | 0.00 | ||
| BCYC | bicycle therapeutics plc | 0.23 | 123,538 | 2,795,660 | reduced | -88.45 | ||
| COGT | cogent biosciences inc | 5.45 | 6,225,640 | 67,236,900 | unchanged | 0.00 | ||
| DAWN | day one biopharmaceuticals inc | 3.50 | 3,103,450 | 43,231,000 | new | |||
| NUVL | nuvalent inc | 13.99 | 1,687,060 | 172,587,000 | reduced | -12.34 | ||
| PTGX | protagonist therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| TERN | terns pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| VRDN | viridian therapeutics inc | 6.36 | 3,445,810 | 78,392,200 | added | 86.68 | ||
| apogee therapeutics inc | 9.76 | 2,048,650 | 120,338,000 | unchanged | 0.00 | |||
| enliven therapeutics inc | 6.63 | 3,202,800 | 81,799,500 | unchanged | 0.00 | |||
| kiniksa pharmaceuticals intl | 6.49 | 3,204,840 | 80,089,000 | unchanged | 0.00 | |||
| oruka therapeutics inc | 6.38 | 3,211,920 | 78,724,200 | new | ||||
| dianthus therapeutics inc | 6.00 | 2,700,690 | 73,944,900 | reduced | -2.25 | |||
| bicara therapeutics inc | 2.65 | 1,284,170 | 32,707,800 | new | ||||
| zenas biopharma inc | 2.60 | 1,892,810 | 32,026,300 | new | ||||